These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9840720)

  • 1. Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel.
    Pronk LC; Hilkens PH; van den Bent MJ; van Putten WL; Stoter G; Verweij J
    Anticancer Drugs; 1998 Oct; 9(9):759-64. PubMed ID: 9840720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral neurotoxicity induced by docetaxel.
    Hilkens PH; Verweij J; Stoter G; Vecht CJ; van Putten WL; van den Bent MJ
    Neurology; 1996 Jan; 46(1):104-8. PubMed ID: 8559354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.
    Hilkens PH; Pronk LC; Verweij J; Vecht CJ; van Putten WL; van den Bent MJ
    Br J Cancer; 1997; 75(3):417-22. PubMed ID: 9020489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to dexamethasone in patients with fluid retention after docetaxel.
    Chan S; Winterbottom L; Gardner S
    Lancet; 1996 May; 347(9013):1486-7. PubMed ID: 8676655
    [No Abstract]   [Full Text] [Related]  

  • 5. The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication.
    Béhar A; Pujade-Lauraine E; Maurel A; Brun MD; Chauvin FF; Feuilhade de Chauvin F; Oulid-Aissa D; Hille D
    Br J Clin Pharmacol; 1997 Jun; 43(6):653-8. PubMed ID: 9205828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study.
    Ferraresi V; Milella M; Vaccaro A; D'Ottavio AM; Papaldo P; Nisticò C; Thorel MF; Marsella A; Carpino A; Giannarelli D; Terzoli E; Cognetti F
    Am J Clin Oncol; 2000 Apr; 23(2):132-9. PubMed ID: 10776972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
    Piccart MJ; Klijn J; Paridaens R; Nooij M; Mauriac L; Coleman R; Bontenbal M; Awada A; Selleslags J; Van Vreckem A; Van Glabbeke M
    J Clin Oncol; 1997 Sep; 15(9):3149-55. PubMed ID: 9294478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
    Valero V; Jones SE; Von Hoff DD; Booser DJ; Mennel RG; Ravdin PM; Holmes FA; Rahman Z; Schottstaedt MW; Erban JK; Esparza-Guerra L; Earhart RH; Hortobagyi GN; Burris HA
    J Clin Oncol; 1998 Oct; 16(10):3362-8. PubMed ID: 9779713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: partial cross-resistance between paclitaxel and docetaxel.
    Lin YC; Chang HK; Wang CH; Chen JS; Liaw CC
    Anticancer Drugs; 2000 Sep; 11(8):617-21. PubMed ID: 11081452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer.
    Shapiro JD; Millward MJ; Rischin D; Davison JD; Michael M; Francis PA; Ganju V; Toner GC
    Aust N Z J Med; 1997 Feb; 27(1):40-4. PubMed ID: 9079252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.
    Bruno R; Hille D; Riva A; Vivier N; ten Bokkel Huinnink WW; van Oosterom AT; Kaye SB; Verweij J; Fossella FV; Valero V; Rigas JR; Seidman AD; Chevallier B; Fumoleau P; Burris HA; Ravdin PM; Sheiner LB
    J Clin Oncol; 1998 Jan; 16(1):187-96. PubMed ID: 9440742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
    Valero V
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel neuropathy.
    Pace A; Bove L; Pietrangeli A; Innocenti P; Jandolo B
    Neurology; 1996 Aug; 47(2):615. PubMed ID: 8757066
    [No Abstract]   [Full Text] [Related]  

  • 14. Docetaxel neuropathy.
    Apfel SC
    Neurology; 1996 Jan; 46(1):2-3. PubMed ID: 8559375
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity.
    Moon C; Verschraegen CF; Bevers M; Freedman R; Kudelka AP; Kavanagh JJ
    Anticancer Drugs; 2000 Aug; 11(7):565-8. PubMed ID: 11036959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks and benefits of taxanes in breast and ovarian cancer.
    Michaud LB; Valero V; Hortobagyi G
    Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
    Chan S
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe syndrome of inappropriate antidiuretic hormone secretion with docetaxel treatment in metastatic breast cancer.
    Langer-Nitsche C; Lück HJ; Heilmann M
    Acta Oncol; 2000; 39(8):1001. PubMed ID: 11206991
    [No Abstract]   [Full Text] [Related]  

  • 19. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
    Chan S; Friedrichs K; Noel D; Pintér T; Van Belle S; Vorobiof D; Duarte R; Gil Gil M; Bodrogi I; Murray E; Yelle L; von Minckwitz G; Korec S; Simmonds P; Buzzi F; González Mancha R; Richardson G; Walpole E; Ronzoni M; Murawsky M; Alakl M; Riva A; Crown J;
    J Clin Oncol; 1999 Aug; 17(8):2341-54. PubMed ID: 10561296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands.
    Kruijtzer CMF ; Verweij J; Schellens JH; Beijnen JH; Pronk L; Bo M; Lustig V; van Tinteren H; Mackay M; Ten Bokkel Huinink WW
    Anticancer Drugs; 2000 Apr; 11(4):249-55. PubMed ID: 10898539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.